oesophageal squamous cell carcinoma
Oncology · 2021–2024
4decisions
2medicines
3carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tislelizumab First-line treatment of patients with unresectable, locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC) in combination with… | Nov 2024 | Recommended with restriction | input received Rare Cancers Australia · Pancare Foundation · Medical Oncology Group |
| nivolumab Advanced or metastatic oesophageal squamous cell carcinoma (OSCC), agnostic to PD-L1 status, in first-line and second-line settings; also gastric cancer,… | Jul 2023 | Recommended with restriction | no section in document |
| nivolumab Second-line treatment of advanced or metastatic oesophageal squamous cell carcinoma after failure of fluoropyrimidine and platinum-based chemotherapy. | Mar 2022 | Recommended | input received Medical Oncology Group |
| nivolumab Treatment of advanced or metastatic oesophageal squamous cell carcinoma in patients who have failed one fluoropyrimidine and platinum-based chemotherapy… | Jul 2021 | Recommended with restriction | input received |
Who spoke
Medical Oncology Group · Rare Cancers Australia · Pancare Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.